Sugi Predict

Sugi Predict / Compounds / SCHEMBL18924053

SCHEMBL18924053

SCHEMBL18924053

COC(=O)[C@H]1CC[C@H](C(=O)NCC(=O)NCC(=O)NCC(=O)OC(C)(C)C)CC1

nearest known ligand 0.38

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ PSMB5 P28074 3/20 0.38
▸ TRPA1 O75762 1/20 0.38
▸ SMN1; SMN2 Q16637 4/20 0.37
▸ HSD17B10 Q99714 2/20 0.37
▸ ALDH1A1 P00352 3/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ TSHR P16473 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.36
▸ HRH3 Q9Y5N1 1/20 0.35
▸ GAA P10253 1/20 0.35
▸ HTT P42858 1/20 0.34
▸ RECQL P46063 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19656336 0.87 PSMB5 (0.39) PSMB5TRPA1SMN1; SMN2HSD17B10ALDH1A1
SCHEMBL24785386 0.87 SMN1; SMN2 (0.51) PSMB5SMN1; SMN2HSD17B10ALDH1A1HRH3
SCHEMBL21319666 0.85 SMN1; SMN2 (0.50) PSMB5SMN1; SMN2HSD17B10ALDH1A1HTT
SCHEMBL17570904 0.82 PSMB5 (0.41) PSMB5SMN1; SMN2ALDH1A1KMT2AGAA
SCHEMBL18924125 0.82 PSMB5 (0.41) PSMB5SMN1; SMN2ALDH1A1KMT2AGAA
SCHEMBL18924055 0.80 PSMB5 (0.44) PSMB5HSD17B10ALDH1A1KMT2ATSHR
SCHEMBL25030100 0.79 TLR2 (0.41) PSMB5TRPA1SMN1; SMN2HSD17B10ALDH1A1
SCHEMBL25030508 0.79 TLR2 (0.41) PSMB5TRPA1SMN1; SMN2HSD17B10ALDH1A1
SCHEMBL4798693 0.78 SMN1; SMN2 (0.39) SMN1; SMN2ALDH1A1KMT2AMEN1TSHR
SCHEMBL16732426 0.75 SMN1; SMN2 (0.41) SMN1; SMN2ALDH1A1KMT2AMEN1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230233697-A1 CYTOTOXIC BENZODIAZEPINE DERIVATIVES IMMUNOGEN, INC. 2023-07-27 — — US disclosed
US-20230233697-A1 CYTOTOXIC BENZODIAZEPINE DERIVATIVES IMMUNOGEN, INC. 2023-07-27 — — US disclosed
US-10722588-B2 Cytotoxic benzodiazepine derivatives IMMUNOGEN, INC. (US) 2020-07-28 — — US disclosed
US-20190269786-A1 CYTOTOXIC BENZODIAZEPINE DERIVATIVES IMMUNOGEN, INC. 2019-09-05 — — US disclosed
US-10238751-B2 Cytotoxic benzodiazepine derivatives IMMUNOGEN, INC. (US) 2019-03-26 — — US disclosed
US-20170340748-A1 CYTOTOXIC BENZODIAZEPINE DERIVATIVES IMMUNOGEN, INC. 2017-11-30 — — US disclosed
US-9669102-B2 Cytotoxic benzodiazepine derivatives IMMUNOGEN, INC. (US) 2017-06-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10238751-B2 Cytotoxic benzodiazepine derivatives GABRA6, GABBR1, GABRA5 PSMB5 1114/4885TRPA1 2922/4885SMN1; SMN2 2324/4885
US-20230233697-A1 CYTOTOXIC BENZODIAZEPINE DERIVATIVES GABRA6, GABBR1, GABRA5 PSMB5 1114/4885TRPA1 2922/4885SMN1; SMN2 2324/4885
US-10722588-B2 Cytotoxic benzodiazepine derivatives GABRA6, GABBR1, GABRA5 PSMB5 1114/4885TRPA1 2922/4885SMN1; SMN2 2324/4885
US-20190269786-A1 CYTOTOXIC BENZODIAZEPINE DERIVATIVES GABRA6, GABBR1, GABRA5 PSMB5 1114/4885TRPA1 2922/4885SMN1; SMN2 2324/4885
US-20170340748-A1 CYTOTOXIC BENZODIAZEPINE DERIVATIVES GABRA6, GABBR1, GABRA5 PSMB5 1114/4885TRPA1 2922/4885SMN1; SMN2 2324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.